“The next decade is the golden decade of innovative medicine in China. I am very convinced of this.”

Wang Junfeng joined Junlian Capital in 2004 and has been focused on non-TMT investments. He has been involved in clean technology, medical health, and smart manufacturing. He is now responsible for Junlian's medical investment. His leading investment projects include high-energy environment (603588.SH), Hanwha New Energy (HQCL.O), Hekang Xinneng (300048.SZ), Kain Technology, Cinda Bio, and Platinum Medicine, Bionano.

In terms of policy, Wang Junfeng said that after 2015, the country has successively issued a series of encouraging policies for innovative drugs. The implementation of these policies has brought about a major change in the living environment of the entire innovative drug.

In addition to innovative medicines, Wang Junfeng believes that another opportunity in the medical field is gene therapy and genetic diagnosis. He said that as genetic technology matures, there will be more and more applications in the subdivision. "With advances in diagnostic technology, oncology treatments can achieve precise, personalized medications. Individualized treatments can produce good results."